CX 2051
Alternative Names: CX-2051Latest Information Update: 10 Apr 2024
At a glance
- Originator ImmunoGen
- Developer CytomX Therapeutics
- Class Antibodies; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 08 Apr 2024 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Inoperable/Unresectable) in USA (Parenteral) (NCT06265688)
- 01 Apr 2024 CytomX Therapeutics plans a phase I trial for Solid tumours including Colorectal cancer (Metastatic disease) in 1H of 2024
- 24 Jan 2024 US FDA approves IND application for CX 2051 in Solid tumours